• 대한방사선치료학회:학술대회논문집
• /
• 2000.06a
• /
• pp.22-22
• /
• 2000

• Radiation Oncology Journal
• /
• v.3 no.1
• /
• pp.51-58
• /
• 1985

This study analyzes fifteen patients who underwent a course of radiation therpy for their vulva cancer in the Department of Radiation Oncology, College of Medicine, Yonsei University from January, 1971 to April, 1985. Four patients had initial surgery for their vulva cancer and were subsequently treated by a course of adjuvant radiation therapy. Eleven patients were given radiation therapy as the initial course of therapy, and one of these was in adjuvant setting before radical surgery. Treatment in each instance was individuilzed and usually consisted of some components of external beam, brachytherapy, and/or electron beam therapy. Primary local control rate in all cases was $53\%(8/15),\;40\%(4/10)$ in the radiation therapy alone group and $80\%(4/5)$ in the radiation therapy combined with surgery group. Treatment failures were noted in 7/10 in the radiation therapy alone group and 2/5 in the radiation therapy combined with surgery group. The most common failure site was primary site failure(vulva).

• 대한방사선치료학회:학술대회논문집
• /
• 2000.06a
• /
• pp.28-28
• /
• 2000

• 대한방사선치료학회:학술대회논문집
• /
• 2000.04a
• /
• pp.6-6
• /
• 2000

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 2003.09a
• /
• pp.33-33
• /
• 2003

목적 : 현재 국내에서 사용되고 있는 방사선치료계획 장비는 거의 모든 방사선종양학과에서 외국 회사의 제품을 사용하고 있는 실정이다. 본 연구는 국내 기술로 개발된 3 차원 조형 방사선치료계획 장비인 Core Plan의 선량계산 알고리즘의 정확성 및 방사선 치료계획 장비로서의 유용성에 관해 평가하고 본 장비의 특징에 대해 간략히 소개하고자 한다. 재료 및 방법 : 본 연구는 2002 년 11 월에 가톨릭대학교 성모병원 방사선종양학과와 서울씨앤제이의 연구계약에 의해 시행되었다. 본 장비에 대한 평가는 방사선분포 및 계산상의 정확성과 임상적용시의 유용성의 관점에서 시행되었다. 본 장비에서 이용된 광자선 선량계산은 Clarkson-Cunningham 모델이며 전자선 선량계산은 2.5D Hogstrom 알고리즘이다. 방사선분포 및 계산상의 정확성 평가를 위하여 방사선치료 장비는 본 병원이 보유한 Clinac 2100CD (Varian, USA)를 이용하였고 폴리스티렌 팬텀과 필름 및 이온 전리함을 이용하여 방사선분포 및 계산상의 정확성을 평가하였다. 방사선분포의 평가 방법은 필름을 이용한 방사선분포의 중심부단면 선량분포와 CorePlan 에서 재현된 방사선분포의 동일면 선량분포를 비교하였다. 임상적용은 2003 년 3 월부터 7 월까지 방사선치료를 받은 50 명의 환자를 대상으로 분석하였다. 본 시험에 적용된 환자는 본 병원이 보유한 3 차원 방사선치료계획 장비인 Prowess 3D (SSGI Inc., USA)를 이용하여 실제 치료된 환자들이며 이 환자를 대상으로 CorePlan에서 동일하게 재현하여 비교하였다. 결과 및 결론 : 방사선분포 및 계산상의 정확성 평가에서는 실제 측정된 결과와 CorePlan에서 재현된 결과가 모두 $\pm$3% 이내로 평가되었다. 50 명의 환자를 대상으로 시행한 임상시험 결과 Prowess 3D에서 나타낸 결과와 비교하여 두경부에서는 1.678%, 흉부 1.578%, 복부 1.271%의 선량값의 오차를 보였다. 본 연구를 진행하는 과정에서 많은 부분의 프로그램 수정이 있었으며 실제임상에 필요한 부분에 대한 추가 및 보완이 이루어졌다. 앞으로 진행될 과정은 실제임상의 사용에 필요한 부분의 계속적인 업그레이드와 전자선에 대한 방사선분포 및 계산정확성 평가, 임상적용에 있어서 Prowess3D 뿐만 아니라 다양한 방사선 치료계획 장비와의 비교를 할 예정이다.

• Radiation Oncology Journal
• /
• v.19 no.3
• /
• pp.230-236
• /
• 2001

Purpose : To evaluate treatment results in terms of local control, complications and survival after reirraidiation in recurrent cervical cancer following definite radiation therapy. Material and methods : From November 1987 through March 1998, eighteen patients with recurrent cervical cancer following definite radiation therapy were subsequently treated with reirradiation at Keimyung University Dongsan Medical Center. In regard to the initial FIGO stage, one patient was stage la, five were stage IIa, three were IIb, two were IIb and two were IVa. The age range was 37 to 79 years old with median age of 57. The time interval from initial definite radiation therapy to recurrence ranged from 6 to 122 months with a median of 58 months. The recurrent sites were the uterine cervix in seven patients, vagina in ten and pelvic lymph node in one. Reirradiation was peformed with external radiation and intracavitary radiation in twelve patients, external radiation and implantation in four and external radiation alone in two. The range of external radiation dose was $2,100\~5,400\;cGy$ and the range of the total radiation dose was $3,780\~8,550\;cGy$. The follow-up periods ranged from 8 to 20 months with median of 25 following reirradiation. Results : Fourteen of eighteen patients $(78\%)$ had local control just after reirradiation. The two year disease free survival (2YDFS) rate was $53.6\%$. There were statistically significant differences in the 2YDFS according to both recurrent site (2YDFS $28.5\%$ in uterine cervix, $71.4\%$ in vagina, (p=0.03)) and the total dose (2YDFS $71.8\%$ in >6,000 cGy , $25\%$ in $\leq6,000$ cGy, p=0.007). Seven of ten patients who were followed for more than 20 months remain alive and disease free (7/18, $39\%$). Patients treated with external radiation and intracavitary radiation had a higher rate of 2YDFS. Seven patients including 4 patients with no local control experienced local failure in the uterus or vagina and two patients died with distant metastasis. Complications included rectal bleeding in 3 patients, bowel obstruction treated with surgery in two, hematuria in one, radiation cystitis in two, soft tissue swelling in two and vaginal necrosis spontaneously healed in one. There was no statistical difference in complications according to the total dose or the time to recurrence from initial radiation. Conclusion : In patients with recurrence following definite radiation therapy in the uterine cervical cancer, reirradiation may be effective but requires an effort to reduce radiation induced severe complications.

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 2005.04a
• /
• pp.39-41
• /
• 2005

본 연구에서는 두경부암 환자에게 세기조절 방사선치료계획을 수립한 후 환자 위치의 정확한 재현성과 치료선량의 정확한 전달을 위한 정도관리를 본원에 설치되어 있는 21ex 선형가속기와 세기조절방사선치료계획 장치인 CORVUS 시스템을 사용하였다. 세기조절 방사선치료계획을 QA 아크릴 팬텀으로 옮겨 계산된 계산치가 1.50 Gy였으며, 같은 조건으로 QA 아크릴 팬텀을 설치하여 측정한 선량은 1.485 Gy였으며, TLD에서의 측정치는 1.483 Gy였다. 측정치의 비교에서 이온챔버와 TLD에서 각각 1.0%, 1.2%의 차이를 보여 세기조절방사선치료의 환자 적용에의 적합성을 확인하였다. 나아가 환자치료시 정확하게 치료되고 있는지에 대한 검정과정을 개발하였다.

• Journal of radiological science and technology
• /
• v.39 no.4
• /
• pp.587-593
• /
• 2016

We are evaluated the usefulness of radiation treatment planning applied respiration factor for stereotactic body radiation therapy in the lung cancer. Four dimensional computed tomography images were obtained in 10 patients with lung cancer. The radiation treatment plans were established total lung volume according to respiration images (new method) and conventional method. We was analyzed in the lung volume, radiation absorbed dose of lung and main organs (ribs, tracheobronchus, esophagus, spinal cord) around the tumor, respectively. We were confirmed that lung volume and radiation absorbed dose of lung and main organs around the tumor deference according to applied respiration. In conclusion, radiation treatment planning applied respiration factor seems to be useful for stereotactic body radiation therapy in the lung cancer.

• The Journal of Korean Society for Radiation Therapy
• /
• v.14 no.1
• /
• pp.15-22
• /
• 2002

1. 목적 : 방사선종양학과에서 3차원 치료계획용 전산화단층촬영 시 조영제 주입율에 따른 CT 값(hounsfield unit, H.U) 변화를 정량적으로 평가하여 최적의 영상증강효과 및 방사선치료계획을 위한 기초 프로토콜을 제시하고자 한다. 2. 대상 및 방법: 연세암센터 방사선종양학과에서 3차원 치료계획용 전산화단층촬영을 시행한 상복부(폐암)환자 20명을 대상으로 하였다. 조영제 양(130mL)은 일정하게 고정하였고, 조영제주입율을 1.2, 1.5, 2.0 mL/sec로 변화시켜가며 조영제를 주입하면서 3차원 방사선치료계획영상에 적합한 조영제주입율(contrast flow rate)과 지연시간(delay time)을 도출하였고, CT 값을 측정하여 정량적 평가를 시행하였다. 관심부위는 폐동맥과 폐정맥으로 하였다. 그리고, 환자 기본정보, 조영제주입율, H.U 등 영상증강에 영향을 미치는 인자들을 통계처리 프로그램인 SPSS를 이용하여 최적의 영상을 획득할 수 있는 기초 프로토콜을 작성하였다. 3. 결과 : 폐암환자의 전산화단층촬영영상 획득 시 3차원 방사선치료계획에 적합한 영상을 얻을 수 있는 조건중 조영제주입율은 1.5 mL/sec 이었고, 지연시간은 $60{\sim}70$초이었다. 통계처리를 수행한 결과 환자의 기본정보 및 조영제주입율 등이 영상증강에 영향을 미치는 인자임을 알 수 있었다. 본 연구에서 작성한 기초 프로토콜을 이용하여 3차원 방사선치료계획 시 정확한 종양 및 정상조직 설정이 용이하게 되어 방사선치료 효율을 극대화 할 수 있었다. 4. 결론 : 방사선종양학과에서 3차원 치료계획용 전산화단층촬영 시 사용할 수 있는 기초적인 영상획득 프로토콜을 도출하였고, 향후 더 많은 임상경험과 정량적 평가가 수반된다면 임상에 적극 사용할 수 있을 것이라 사료된다.

• Radiation Oncology Journal
• /
• v.17 no.2
• /
• pp.113-119
• /
• 1999

Purpose : To evaluate possible acute toxicity and early response of concurrent radiation therapy and low dose daily cisplatin as a radiosensitizer in patients with locally advanced uterine cervical carcinomas. Materials and Method : From December 1996 to January 1999, 38 previously untreated Patients with locally advanced squamous cell carcinoma of the uterine cervix (from stage IIB to stage IIIB) were treated at Inha University Hospital. All patients underwent standard pretreatment staging Procedures after the initial evaluation by gynecologists and radiation oncologists. Sixteen Patients with huge cervical mass (>4 cm) were submitted to the group treated with concurrent radiation therapy and low dose daily cisplatin while the remainder was treated with radiation therapy alone. Radiation therapy consisted of 4500 cGy external beam irradiation to whole pelvis (midline block after 3000 cGy), 900$\~$1000 cGy boost to involved parametrium, and high dose-rate intracavitary brachytherapy (a total dose of 3000$\~$3500 cGy/500 cGy per fraction to point A, twice per week). In the group treated with low dose cisplatin concurrently, 10 mg of daily intravenous cisplatin was given from the 1st day of radiation therapy to the 20th day of radiation therapy. Acute toxicity was measured according to expanded common toxicity criteria of the NCI (C) Clinical Trials. Early response data were analyzed at minimum 4 weeks' follow-up after completion of the treatment protocol. Results: Hematolgic toxici쇼 was more prominent in patients treated with radiation therapy and cisplatin. Six of 16 patients (37.5$\~$) treated with radiation therapy and cisplatin and one of 22 patients (4.5$\~$) treated with radiation therapy alone experienced grade 3 leukopenia. In Fisher's exact test, there was statistically significant difference between two groups regarding leukopenia (P=0.030). There was no apparent difference in the frequency of gastrointestinal and genitourinary toxicity between two groups (P=0.066). Three of 16 patients (18.7$\~$) treated with radiation therapy and cisplatin and two of 22 patients (9.1$\~$) treated with radiation therapy alone experienced more than 5 kg weight loss during the treatment. There was no statistically significant difference on weight loss between two groups (P=0.63). Two patients on each group were not evaluable for the early response because of incomplete treatment. The complete response rate at four weeks' follow-up was 80$\~$(16/20) for the radiation therapy alone group and 78$\~$ (11/14) for the radiation therapy and cisplatin group. There was no statistically significant difference in early response between two treatment groups (P=0.126). Conclusion : This study led to the conclusion that the hematologic toxicity from the treatment with concurrent radiation therapy and low dose daily cisplatin seems to be more prominent than that from the treatment of radiation therapy alone. There was no grade 4 hematologic toxicity or mortality in both groups. The hematologic toxicity in both treatment groups seems to be well managable modically. Since the risk factors were not balanced between two treatment groups, the direct comparison of early response of both groups was not possible. However, preliminary results regarding early response for patients with bulky cervical tumor mass treated with radiation therapy and low dose daily cisplatin was encouraging. Longer follow-up is necessary to evaluate the survival data. A phase III study is needed to evaluate the efficacy of concurrent daily low dose cisplatin with radiation therapy in bulky cervical cancer.